

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

**MYLAN PHARMACEUTICALS INC.,
Petitioner,**

v.

**POZEN INC. and HORIZON PHARMA USA, INC.,
Patent Owners.**

**Case No. IPR2017-01995
Patent 9,220,698**

JOINT NOTICE OF STIPULATION TO ADJUST SCHEDULE

Further to the Scheduling Order dated March 8, 2018 (Paper 19), the parties hereby jointly request entry of the present Joint Notice of Stipulation to Adjust Schedule.

Patent Owners and Petitioner have conferred and reached an agreement regarding an adjustment to DUE DATE 1 in order to facilitate scheduling of cross-examination in the first patent owner discovery period. The parties hereby stipulate to, and jointly request entry of, the adjustment to the Schedule as follows.

	ORIGINAL DATE	NEW AGREED DATE
DUE DATE 1	May 30, 2018	June 1, 2018

This joint stipulation does not affect or modify the dates for DUE DATE 2 through DUE DATE 7.

Dated: May 9, 2018

Respectfully submitted,

/s/ Thomas A. Blinka

Thomas A. Blinka, Ph.D.
Registration No. 44,541
COOLEY LLP
ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington, DC 20004
Counsel for Patent Owner

/s/ Brandon M. White

Brandon M. White
Reg. No. 52,354
Perkins Coie LLP
700 13th St., NW, Suite 600
Washington, D.C. 20005
Telephone: (202) 654-6206
E-mail: bmwhite@perkinscoie.com
Counsel for Petitioner

CERTIFICATE OF SERVICE

I, Thomas A. Blinka, hereby certify that on this 9th day of May 2018, the foregoing **JOINT NOTICE OF STIPULATION TO ADJUST SCHEDULE** was served via email on the following:

Brandon M. White
PERKINS COIE LLP
700 13th St., NW Suite 600
Washington, DC 20005
bmwhite@perkinscoie.com

Emily Greb
PERKINS COIE LLP
One East Main St., Suite 201
Madison, WI 53703
egreb@perkinscoie.com

EsoNaproxen@perkinscoie.com

Dated: May 9, 2018

/s/ Thomas A. Blinka

Thomas A. Blinka
Registration No. 44,541
Counsel for Patent Owner